| (Values in U.S. Thousands) | Sep, 2016 | Sep, 2015 | Sep, 2014 | Sep, 2013 | Sep, 2012 |
| Sales | 68,780 | 39,980 | 24,170 | 27,970 | 10,340 |
| Sales Growth | +72.04% | +65.41% | -13.59% | +170.50% | +444.21% |
| Net Income | -7,140 | -190 | -7,450 | -3,050 | -20,560 |
| Net Income Growth | -3,657.91% | +97.45% | -144.26% | +85.17% | -171.60% |
Merus Labs Intl Inc (MSLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company's products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada.
Fiscal Year End Date: 09/30